Alberto Álvarez‐Larrán

Hospital Clínic de Barcelona — Spain

Medicine · Health Sciences

44h-index6.1kcitations249works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Myeloproliferative Neoplasms: Diagnosis and Treatment(186), Kruppel-like factors research(76), Chronic Myeloid Leukemia Treatments(74), Eosinophilic Disorders and Syndromes(73), Acute Myeloid Leukemia Research(51)

Publications249 total

European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis
Blood Cancer Journal·2025Open Access
Optical genome mapping in myelofibrosis: enhancing prognostic accuracy through high-resolution genomic profiling
Blood Advances·2025Open Access
Coexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study
American Journal of Hematology·2025Open Access
Proteomic profiling links complement activation to thrombosis in JAK2V617F myeloproliferative neoplasms
Translational Oncology·2025Open Access
European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis.
2025Open Access
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study
Blood Cancer Journal·2025· 4 citedOpen Access
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
Nature Medicine·2025· 17 citedOpen Access
Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real‐world ERNEST‐2 registry
HemaSphere·2025· 1 citedOpen Access
Endothelial Damage in JAK2V617F Myeloproliferative Neoplasms with Splanchnic Vein Thrombosis
Thrombosis and Haemostasis·2025· 6 cited
Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis
Blood·2024· 6 cited
New Criteria for Evaluating Outcomes of Myelofibrosis Therapy
Blood·2024Open Access
Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia
Blood·2024
Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia
Blood·2024· 3 citedOpen Access
ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options
Blood·2024
Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia
Leukemia·2024· 2 cited
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis
Leukemia·2024
MPN-135 Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naïve Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
Clinical Lymphoma Myeloma & Leukemia·2024
Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naïve Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
Clinical Lymphoma Myeloma & Leukemia·2024
Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia
2024Open Access
REVEAL puts leukocytes into risk stratification
Blood·2024Open Access
page 1 of 13Next →

Frequent Co-authors

Francisco Cervantes(24), Juan Carlos Hernández‐Boluda(23), Beatríz Bellosillo(14), Eduardo Arellano‐Rodrigo(12), Anna Angona(12), Arturo Pereira(11), Francisca Ferrer‐Marín(10), Carlos Besses(9), Valentín García‐Gutiérrez(9), Tiziano Barbui(8), Alessandra Carobbio(8), Alessandro M. Vannucchi(8), Montse Gómez(8), Carles Besses(8), Luz Martínez‐Avilés(8), Manuel Pérez‐Encinas(8), Dolors Colomer(7), Paola Guglielmelli(7), Carmen Burgaleta(7), Ana Kerguelen(7)